Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2020 08:00 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at the 29th Annual Credit Suisse Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
November 09, 2020 07:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update

Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021 Dosing in three new clinical trials with novel compounds incorporating PN...
October 26, 2020 16:05 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020

CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
September 28, 2020 16:05 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
September 23, 2020 07:00 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
September 22, 2020 16:01 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
September 15, 2020 07:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
September 10, 2020 16:25 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
August 10, 2020 07:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020 ADAR editing...
August 06, 2020 08:00 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast

Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD Platform advancements to be shared include new in vivo RNA editing data Live webcast scheduled for...